Study: U.S. Faces Higher Drug Shortages
November 1, 2024
-
2 min
A recent study compared drug shortage risks following supply chain disruptions between the U.S. and Canada from 2017 to 2021. The findings indicated that the U.S. experienced approximately a 40% higher drug shortage risk compared to Canada, with trends persisting both pre-pandemic and during COVID-19. The study also highlighted that sole-source drugs faced a higher risk of shortage in both countries. Canada's approach, characterized by mandatory reporting, targeted stockpiling, and public payer collaboration, was associated with a lower shortage risk. These differences in drug shortage risks may inform future policy discussions on mitigating supply chain disruptions.
1. Drug shortage risks were compared between the U.S. and Canada from 2017 to 2021. 2. The U.S. experienced approximately a 40% higher drug shortage risk compared to Canada. 3. Canada's approach included mandatory reporting, targeted stockpiling, and public payer collaboration. 4. The study highlighted that sole-source drugs faced a higher risk of shortage in both countries. 5. Canada's approach was associated with a lower shortage risk.
Listen Tab content
